-
公开(公告)号：US20190248910A1
公开(公告)日：2019-08-15
申请号：US16382645
申请日：2019-04-12
Applicant: Janssen Biotech, Inc
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
-
Patent Agency Ranking
22.发明授权ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions 有权ST2L抗体拮抗剂用于治疗ST2L介导的炎症性肺病公开(公告)号：US09212227B2
公开(公告)日：2015-12-15
申请号：US13798226
申请日：2013-03-13
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiun Wu
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
公开(公告)号：US20150299330A1
公开(公告)日：2015-10-22
申请号：US14790144
申请日：2015-07-02
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
公开(公告)号：US20140328837A1
公开(公告)日：2014-11-06
申请号：US14338391
申请日：2014-07-23
Applicant: Janssen Biotech, Inc.
Inventor： Daphne Ann Salick Ryan , John Kehoe , John Wheeler , Chunlin Yang , Abla Creasy
IPC: A61K47/42 , A61K39/395
CPC classification number: A61K47/42 , A61K39/3955 , A61K2039/505 , C07K7/08 , C07K14/525 , C07K16/241 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.
Abstract translation: 我们已经向英夫利昔单抗公开了亲和肽。 更具体地，我们已经公开了一种亲和力生物基质，其中亲和肽共价连接到生物相容的可生物降解的聚合物上。 亲和力生物基质可用于制备英夫利昔单抗的控制释放装置。
-
公开(公告)号：US20130336980A1
公开(公告)日：2013-12-19
申请号：US13798204
申请日：2013-03-13
Applicant: Janssen Biotech, Inc.
Inventor： Karen Duffy , Natalie Fursov , LeRoy Hall , Catherine Healy , Roberta Lamb , Jinquan Luo , Ravi Malaviya , Michael Naso , Michael Pratta , Mark Tornetta , John Wheeler , Sheng-Jiu Wu
IPC: C07K16/28
CPC classification number: C07K16/2866 , A61K38/012 , A61K39/3955 , A61K2039/505 , C07K16/44 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing.
Abstract translation: 本发明涉及ST2L拮抗剂，编码拮抗剂或其片段的多核苷酸，以及制备和使用上述物质的方法。
-
公开(公告)号：US20130243795A1
公开(公告)日：2013-09-19
申请号：US13835518
申请日：2013-03-15
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
-
-
-
-
Search Results
26
records
(took 0.029 seconds)
